Research and Markets: Analysis of the European Multiple Sclerosis Market

Research and Markets (http://www.researchandmarkets.com/research/bfc499e5/analysis_of_the_eu) has announced the addition of Frost & Sullivan's new report "Analysis of the European Multiple Sclerosis Market" to their offering.

European MS Market in Urgent Need of Novel Treatment and Diagnostic Options

Limited awareness about the disease and its overall occurrence and progression among end-users is hampering the European multiple sclerosis (MS) market. This is being exacerbated by the limited availability of accurate diagnostic tools. There is, therefore, an immediate need for innovative and enhanced therapeutic and diagnostic tools that support improved diagnosis and expand the range of treatment options. The rising number of people suffering from MS is resulting in higher demand for related therapeutics, notes the analyst of this research. This, coupled with strong pipeline development, is pushing robust growth in the overall market.

MS is characterised as a chronic disease, commonly diagnosed in patients between 20-50 years of age. It affects more than 2.5 million people across the world, with Europe accounting for nearly 550,000 cases. Significant research is currently underway to efficiently treat MS. Innovative treatment therapies, including biologics and oral drugs, are favouring market prospects. Refined drug delivery technologies, mode of drug delivery (oral or injectable), and several other factors will encourage the use of MS drugs among patients, adds the analyst. Novel treatment options will also promote the concept of combination therapies, accelerating market development.

Awareness Raising will be Key to Promoting Adoption of Novel Treatment Options

A key challenge at present is the inaccuracy in disease diagnosis due to the lack of sensitive diagnostic tools. Another issue is the absence of established treatment procedures. Non-compliance with MS treatment procedures remains a major challenge. Establishing end-user confidence has become difficult due to unsatisfactory therapeutic results. Cumbersome and painful procedures discourage the progress of therapy. Simple advances, like the use of oral drugs instead of injections, will prove beneficial to promoting compliance with therapeutic regimes.

Expert Frost & Sullivan analysts thoroughly examine the following product segments in this research:

- Immunosuppressants

- Immunomodulators

- Corticosteroids

Excerpt from:
Research and Markets: Analysis of the European Multiple Sclerosis Market